Serum test identifies patients deriving benefit from CPIs 193 5 19. Roder, H., Oliveira, C., Net, L., Linstid, B., Tsypin, M., Roder, J. Robust Identification of Molecular Phenotypes using Semi-Supervised Learning. BMC Bioinformatics. 2019;20:273. 20. Weber, J. et al. Pre-treatment patient selection for nivolumab benefit based on serum mass spectra. J Immunother Cancer. 2015:3(Suppl 2):P103. 21. Grossi, F. et al. Evaluation of Pretreatment Serum Tests for Nivolumab Benefit in Patients with Non-Small Cell Lung Cancer. J Thorac Oncol. 2017;12(1):S1322. 22. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545-50. 23. Grigorieva, J., Asmellash, S., Oliveira, C., Roder, H., Net, L., Roder, J. Application of protein set enrichment analysis to correlation of protein functional sets with mass spectral features and multivariate proteomic tests. Clin Mass Spectrometry. 2020; 15:44-53. 24. Roder, J., Linstid, B., Oliveira, C. Improving the power of gene set enrichment analyses. BMC Bioinformatics 2019; 20:257. 25. Benjamini, Y., Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J Royal Stat Soc. Series B (Methods). 1995;57:289-300. 26. Goldberg, S.B. et al. Mass spectrometry-based test predicts outcome on anti-PD-1 therapy for patients with advanced non-small cell lung cancer with brain metastases. J Immunother Cancer. 2017;5(Suppl 2):86. 27. Rutkowski, M.J., Sughrue, M.E., Kane, A.J., Mills, S.A., Parsa, A.T. Cancer and the complement cascade. Mol Cancer Res. 2010;8(11):1453-65. 28. Wang, Y. et al. Autocrine complement inhibits IL10 dependent T-cell-mediated antitumor immunity to promote tumor progression. Cancer Disc. 2016:6;1022-1035. 29. Ajona, D. et al. Investigation of complement activation product C4D as a diagnostic and prognostic biomarker for lung cancer. J Natl Cancer Inst. 2013;105(18):1385-93. 30. McMillan, D.C. The systemic inflammation-based Glasgow score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39:534-40. 31. Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165:35-44. 32. Chang, H.Y. et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biology. 2004;2:0206. 33. Kowanetz, M. et al. Evaluation of immune-related markers in the circulating proteome and their assocation with atezolizumab efficacy in patients with 2L+ NSCLC. J Immunother Cancer 2018;6(Suppl 1):114.
RkJQdWJsaXNoZXIy MTk4NDMw